Tower Research Capital (TRC)’s Niagen Bioscience NAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $13.3K | Sell |
4,171
-2,683
| -39% | -$10.9K | ﹤0.01% | 3863 |
|
|
2026
Q1 | $30.2K | Buy |
6,854
+2,463
| +56% | +$13.3K | ﹤0.01% | 3159 |
|
|
2025
Q4 | $27.9K | Buy |
4,391
+423
| +11% | +$2.94K | ﹤0.01% | 2853 |
|
|
2025
Q3 | $37K | Sell |
3,968
-2,453
| -38% | -$24.8K | ﹤0.01% | 2757 |
|
|
2025
Q2 | $92.5K | Buy |
6,421
+2,835
| +79% | +$28K | ﹤0.01% | 2446 |
|
|
2025
Q1 | $24.7K | Buy |
3,586
+2,318
| +183% | +$14.6K | ﹤0.01% | 2775 |
|
|
2024
Q4 | $6.73K | Sell |
1,268
-2,102
| -62% | -$11.5K | ﹤0.01% | 4142 |
|
|
2024
Q3 | $12.3K | Sell |
3,370
-9,508
| -74% | -$29.9K | ﹤0.01% | 3602 |
|
|
2024
Q2 | $35.2K | Buy |
12,878
+12,778
| +12,778% | +$42.8K | ﹤0.01% | 3366 |
|
|
2024
Q1 | $348 | Buy |
100
+91
| +1,011% | +$168 | ﹤0.01% | 5537 |
|
|
2023
Q4 | $13 | Sell |
9
-4,439
| -100% | -$6.18K | ﹤0.01% | 5834 |
|
|
2023
Q3 | $6.49K | Buy |
4,448
+3,551
| +396% | +$5.55K | ﹤0.01% | 4589 |
|
|
2023
Q2 | $1.41K | Sell |
897
-4,453
| -83% | -$6.65K | ﹤0.01% | 5383 |
|
|
2023
Q1 | $9K | Sell |
5,350
-13,489
| -72% | -$24K | ﹤0.01% | 4560 |
|
|
2022
Q4 | $31K | Buy |
18,839
+5,528
| +42% | +$8.77K | ﹤0.01% | 2728 |
|
|
2022
Q3 | $16K | Sell |
13,311
-27,030
| -67% | -$43.5K | ﹤0.01% | 4146 |
|
|
2022
Q2 | $67K | Buy |
40,341
+35,071
| +665% | +$68.6K | ﹤0.01% | 2627 |
|
|
2022
Q1 | $13K | Buy |
5,270
+740
| +16% | +$2.02K | ﹤0.01% | 4009 |
|
|
2021
Q4 | $17K | Sell |
4,530
-5,601
| -55% | -$30.2K | ﹤0.01% | 3877 |
|
|
2021
Q3 | $64K | Buy |
10,131
+8,069
| +391% | +$66.5K | ﹤0.01% | 2766 |
|
|
2021
Q2 | $20K | Sell |
2,062
-32,037
| -94% | -$279K | ﹤0.01% | 3902 |
|
|
2021
Q1 | $319K | Buy |
34,099
+15,814
| +86% | +$125K | 0.01% | 1624 |
|
|
2020
Q4 | $88K | Sell |
18,285
-28,149
| -61% | -$137K | ﹤0.01% | 2478 |
|
|
2020
Q3 | $186K | Buy |
46,434
+36,743
| +379% | +$177K | ﹤0.01% | 2646 |
|
|
2020
Q2 | $44K | Buy |
9,691
+6,341
| +189% | +$28.4K | ﹤0.01% | 3146 |
|
|
2020
Q1 | $11K | Buy |
3,350
+1,524
| +83% | +$5.85K | ﹤0.01% | 1996 |
|
|
2019
Q4 | $8K | Sell |
1,826
-2,952
| -62% | -$10.5K | ﹤0.01% | 2473 |
|
|
2019
Q3 | $19K | Buy |
+4,778
| New | +$20.4K | ﹤0.01% | 2519 |
|
|
2019
Q1 | – | Sell |
-4,545
| Closed | -$16K | – | 4364 |
|
|
2018
Q4 | $16K | Buy |
4,545
+4,324
| +1,957% | +$15K | ﹤0.01% | 2132 |
|
|
2018
Q3 | $1K | Sell |
221
-614
| -74% | -$2.64K | ﹤0.01% | 3641 |
|
|
2018
Q2 | $3K | Buy |
+835
| New | +$3.17K | ﹤0.01% | 3264 |
|
|
2017
Q4 | – | Sell |
-1,159
| Closed | -$5K | – | 4112 |
|
|
2017
Q3 | $5K | Buy |
1,159
+487
| +72% | +$1.78K | ﹤0.01% | 3339 |
|
|
2017
Q2 | $3K | Buy |
+672
| New | +$2.13K | ﹤0.01% | 2254 |
|
|
2017
Q1 | – | Sell |
-572
| Closed | -$2K | – | 4049 |
|
|
2016
Q4 | $2K | Buy |
+572
| New | +$1.55K | ﹤0.01% | 3483 |
|
|
2016
Q3 | – | Sell |
-1,089
| Closed | -$5K | – | 4584 |
|
|
2016
Q2 | $5K | Buy |
+1,089
| New | +$5.15K | ﹤0.01% | 3427 |
|
Other funds holding NAGE
SW
TCM
Tower Research Capital (TRC)'s NAGE Position: Q2 2026 in Review
Tower Research Capital (TRC) reduced its Niagen Bioscience (NAGE) stake by 39% in Q2 2026, selling an estimated $10.9K and leaving 4,171 shares worth $13.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3863.
Tower Research Capital (TRC) first reported a position in NAGE in Q2 2016 and has held it in 35 quarters since. The position peaked at $319K in Q1 2021. 139 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.
- Tower Research Capital (TRC) held 4,171 shares of Niagen Bioscience worth $13.3K as of Q2 2026.
- Tower Research Capital (TRC) sold 2,683 Niagen Bioscience shares in Q2 2026, an estimated $10.9K.
- Niagen Bioscience made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3863 holding.
- Tower Research Capital (TRC) first reported a position in Niagen Bioscience in Q2 2016 and has held it in 35 quarters since.
- Tower Research Capital (TRC)'s Niagen Bioscience position peaked at $319K in Q1 2021.
- 139 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.